[HTML][HTML] Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients …
C Saberian, RN Amaria, AM Najjar… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background The adoptive transfer of tumor-infiltrating lymphocytes (TIL) has demonstrated
robust efficacy in metastatic melanoma patients. Tumor antigen–loaded dendritic cells (DCs) …
robust efficacy in metastatic melanoma patients. Tumor antigen–loaded dendritic cells (DCs) …
Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with …
C Saberian, RN Amaria, AM Najjar… - Journal for …, 2021 - search.proquest.com
Background The adoptive transfer of tumor-infiltrating lymphocytes (TIL) has demonstrated
robust efficacy in metastatic melanoma patients. Tumor antigen–loaded dendritic cells (DCs) …
robust efficacy in metastatic melanoma patients. Tumor antigen–loaded dendritic cells (DCs) …
Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with …
C Saberian, RN Amaria, AM Najjar… - … for Immunotherapy of …, 2021 - europepmc.org
Background The adoptive transfer of tumor-infiltrating lymphocytes (TIL) has demonstrated
robust efficacy in metastatic melanoma patients. Tumor antigen–loaded dendritic cells (DCs) …
robust efficacy in metastatic melanoma patients. Tumor antigen–loaded dendritic cells (DCs) …
[HTML][HTML] Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients …
C Saberian, RN Amaria, AM Najjar… - … for ImmunoTherapy of …, 2021 - jitc.bmj.com
Background The adoptive transfer of tumor-infiltrating lymphocytes (TIL) has demonstrated
robust efficacy in metastatic melanoma patients. Tumor antigen–loaded dendritic cells (DCs) …
robust efficacy in metastatic melanoma patients. Tumor antigen–loaded dendritic cells (DCs) …
Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with …
C Saberian, RN Amaria… - Journal for …, 2021 - mdanderson.elsevierpure.com
Background The adoptive transfer of tumor-infiltrating lymphocytes (TIL) has demonstrated
robust efficacy in metastatic melanoma patients. Tumor antigen-loaded dendritic cells (DCs) …
robust efficacy in metastatic melanoma patients. Tumor antigen-loaded dendritic cells (DCs) …
Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with …
C Saberian, RN Amaria, AM Najjar… - Journal for …, 2021 - pubmed.ncbi.nlm.nih.gov
Background The adoptive transfer of tumor-infiltrating lymphocytes (TIL) has demonstrated
robust efficacy in metastatic melanoma patients. Tumor antigen-loaded dendritic cells (DCs) …
robust efficacy in metastatic melanoma patients. Tumor antigen-loaded dendritic cells (DCs) …
Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with …
C Saberian, RN Amaria, AM Najjar… - … for Immunotherapy of …, 2021 - europepmc.org
Background The adoptive transfer of tumor-infiltrating lymphocytes (TIL) has demonstrated
robust efficacy in metastatic melanoma patients. Tumor antigen–loaded dendritic cells (DCs) …
robust efficacy in metastatic melanoma patients. Tumor antigen–loaded dendritic cells (DCs) …